Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Non-Hodgkin

Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.

2,778 public trials 699 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Non-Hodgkin trial results

Completed

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

NCT02956382

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Georgetown Lombardi Comprehensive Cancer Center Washington D.C., District of Columbia, United States
  • John Theurer Cancer Center at Hackensack University Medical Center Hackensack, New Jersey, United States
  • Seattle Cancer Care Alliance Seattle, Washington, United States
View Trial Details
Completed

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT02763319

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • MorphoSys Research Site Anaheim, California, United States
  • MorphoSys Research Site Bakersfield, California, United States
  • Morphosys Research Site Burbank, California, United States
  • Morphosys Research Site Fresno, California, United States
View all 158 locations
View Trial Details
Completed

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

NCT03144674

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • University of Alabama At Birmingham Comprehensive Cancer Center Birmingham, Alabama, United States
  • Arizona Oncology Associates Tempe, Arizona, United States
  • Torrance Health Association Redondo Beach, California, United States
  • Sansum Clinic Santa Barbara, California, United States
View all 86 locations
View Trial Details
Completed

Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

NCT04477486

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • NHO Nagoya Medical Center /ID# 221958 Nagoya, Aichi-ken, Japan
  • Aichi Cancer Center Hospital /ID# 221565 Nagoya, Aichi-ken, Japan
  • Kyushu University Hospital /ID# 223299 Fukuoka, Japan
  • Hokkaido University Hospital /ID# 221662 Sapporo, Hokkaido, Japan
View Trial Details
Completed

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

NCT02329080

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Facultni nemocnice Brno, Czechia
  • FNKV (Facultni Nemocnice Kralovske Vinohrady) Prague, Czechia
  • Vseobecna facultni nemocnice v Praze Prague, Czechia
  • Spedali Civili Brescia, Italy
View all 36 locations
View Trial Details
Completed

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT01776840

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Tucson, Arizona, United States
  • Burbank, California, United States
  • La Jolla, California, United States
  • Stanford, California, United States
View all 201 locations
View Trial Details

Related conditions